Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PRO
Autor: | Daniel M Jennings, Stewart McConnell, Metod Oblak, Sam Salek, Roger Else, Saad Al-Ismail, Adele K Fielding, Marina Karakantza, Jonathan Kell, Esther Oliva, Tatyana Ionova, Magda J Al-Obaidi, Graham P. Collins, Catherine Langton, Pushpendra Goswami |
---|---|
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
medicine.medical_specialty 03 medical and health sciences 0302 clinical medicine Quality of life Cronbach's alpha Internal medicine medicine Outpatient clinic Pharmacology (medical) Medical diagnosis Reliability (statistics) Original Research Pharmacology hematological malignancy reliability business.industry lcsh:RM1-950 Hematology-Specific Patient-Reported Outcome Measure clinical practice lcsh:Therapeutics. Pharmacology 030104 developmental biology Clinical research quality of life clinical research 030220 oncology & carcinogenesis symptoms Observational study Patient-reported outcome business internal-consistency |
Zdroj: | Frontiers in Pharmacology Frontiers in Pharmacology, Vol 11 (2020) |
ISSN: | 1663-9812 |
Popis: | Background Patients' experience of symptoms often goes undetected during consultation in an outpatient clinic, and the use of a patient-reported outcome measure (PRO) in such a setting could be useful to aid treatment decision-making. A new PRO measure, the HM-PRO (Hematological Malignancy Specific Patient-Reported Outcome Measure) has been recently developed to evaluate hematological malignancy (HM) patients' health-related quality of life (HRQoL) and their symptom experience in daily clinical practice as well as in research. The objectives of the study were to assess: the internal consistency of the scores for Part A (impact) and its four domains (physical behavior; social well-being; emotional behavior; and eating and drinking habits) and Part B (signs and symptoms); and the test-retest reliability of the individual items of the newly developed hematological malignancy specific composite measure, the HM-PRO. Methods This was a prospective longitudinal observational study where 150 patients with different HMs and different stage of disease (male n = 98 (65.3%); mean age 64.9 ± 14.4 years, range 17.9-89.2 years; mean time since diagnosis 3.7 ± 4.9 years, range 0.04-25.8 years) completed the HM-PRO at baseline (assessment 1 at t1) and after 7 days (assessment 2 at t2). Data analysis was performed using IBMSPSS 23 statistical software. Results The Cronbach's alpha estimates of the HM-PRO for both assessment points (t1 and t2) were above 0.9 for Part A, and above 0.8 for Part B, showing strong stability of the measurement. The level of agreement for the reproducibility between the two assessments, using intra-class correlation coefficients (ICC), was very strong with Part A: ICC = 0.93 (95% CI = 0.90-0.95), and Part B: ICC = 0.91 (0.88-0.93). The ICC for the four domains of Part A ranged from 0.85-0.91. The ICC was greater than 0.8 for overall score of Part A and Part B for all the 10 diagnoses, confirming strong reliability. Conclusion This study clearly indicates that the HM-PRO possesses strong test-retest reliability for both Part A and Part B. The Cronbach's alpha confirmed acceptable internal consistency. The extensive reliability testing described in this study supports the generic nature of the HM-PRO for use in hematological malignancies in both routine clinical practice, to aid treatment decisions, as well as in research. |
Databáze: | OpenAIRE |
Externí odkaz: |